Cyclic tmp | 6453-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Cyclic tmp
• 英文别名: 1-[(6R)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-5-methylpyrimidine-2,4-dione
• CAS: 6453-60-7
• 化学式: C₁₀H₁₃N₂O₇P
• 分子量: 304.19
• InChiKey: QSJFDOVQWZVUQG-KAVNDROISA-N

物化性质

• 密度：
  1.66±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Liquid protein formulations containing thiamine pyrophosphate (TPP)
  申请人：EAGLE BIOLOGICS, INC.

  公开号：US10821184B2

  公开（公告）日：2020-11-03

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。此类制剂可通过皮下注射或肌肉注射快速方便地给药，而无需长时间静脉注射。这些制剂包括低分子量和/或高分子量蛋白质，如 mAbs 和有机磷。加入一种或多种有机磷后，制剂的粘度会大大降低。
• LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES
  申请人：Arsia Therapeutics, Inc.

  公开号：US20150071921A1

  公开（公告）日：2015-03-12

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
• Liquid Protein Formulations Containing Organophosphates
  申请人：EAGLE BIOLOGICS, INC.

  公开号：US20180153997A1

  公开（公告）日：2018-06-07

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
• US9913905B2
  申请人：——

  公开号：US9913905B2

  公开（公告）日：2018-03-13
• [EN] POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS<br/>[FR] FORMULATIONS DE POLYSACCHARIDES ET D'ACIDES NUCLÉIQUES CONTENANT DES AGENTS RÉDUCTEURS DE VISCOSITÉ
  申请人：ARSIA THERAPEUTICS INC

  公开号：WO2016054259A1

  公开（公告）日：2016-04-07

  Concentrated, low-viscosity, low- volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high- molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.